Genitourinary Cancers Symposium

Regarding safety, the investigators did not observe any grade 3 or 4 adverse events during the study.

A higher dose of radiation therapy led to longer progression-free, cancer-specific, and overall survival, compared with the standard dose, in combination with long-term ADT in patients with high-risk prostate cancer.

Benjamin H. Lowentritt, MD, FACS, discusses findings from a United States real-world study of patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide.

Research suggests that combining cabozantinib with atezolizumab could emerge as a promising alternative for individuals facing metastatic castration-resistant prostate cancer that has advanced after novel hormonal therapy.

Oncological outcomes improved with the addition of abiraterone acetate (Zytiga) plus prednisone (AAP) and apalutamide (Erleada) after radical prostatectomy and did not significantly affect health-related quality of life.

A promising new treatment combination of frontline olaparib plus abiraterone/prednisone has emerged for advanced prostate cancer with specific genetic alterations.

Prior treatment with external beam radiation therapy did not increase incidence of hematological toxicity relative to the overall population of patients with metastatic castration-resistant prostate cancer treated with radium-223.

While germline and somatic testing is standard of care in the metastatic castration-resistant prostate cancer setting, it is still underutilized in the real world, leading to negative impacts on therapeutic offerings.

Patients with metastatic hormone-sensitive prostate cancer treated with darolutamide plus androgen deprivation therapy and docetaxel had lower rates of hospitalizations but marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy, and docetaxel.

Neeraj Agarwal, MD, highlights several exciting prostate cancer developments being presented at the upcoming 2024 Genitourinary Cancers Symposium.

Patients with advanced renal cell carcinoma showed positive improvements in survival and toxicity outcomes when given nivolumab monotherapy, salvage nivolumab, and ipilimumab.

In the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.

Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.

Nivolumab and sunitinib combined in the first-line treatment continues to maintain benefit for patients with advanced or metastatic renal cell carcinoma.

The phase 3 ZIRCON trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma met its end point by exceeding high sensitivity and specificity thresholds.

Cabozantinib improved outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among poor-risk patients in combination with nivolumab and ipilimumab.

Early data from the phase 2 CaboPoint trial shows a promising response rate among patients with advanced renal cell carcinoma that progressed after checkpoint inhibitor based combination therapy.

Final overall survival data from two arms of the phase 3 IMvigor130 trial display the potential for atezolizumab in addition to chemotherapy for patients with urothelial carcinoma.

Extended follow-up findings of the phase 3 CheckMate 274 study further support the use of nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma following radical resection.

Pembrolizumab generated antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer, according to cohort B of the phase 2 Keynote-057 trial.

The PARP inhibitor rucaparib bested physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer in the phase 3 TRITON3 study.

Sacituzumab govitecan-hziy demonstrated a promising objective response rate in platinum-ineligible patients with metastatic urothelial cancer after progression on an immune checkpoint inhibitor.

Patients diagnosed with bone metastatic, castration-resistant prostate cancer and treated with radium-223 showed lower incidences of treatment-related adverse events or treatment discontinuation, particularly when used in the front-line setting.

Yann-Alexandre Vano, MD, discusses the main findings from the phase 2 BIONIKK trial that were presented at the 2023 Genitourinary Cancers Symposium.

Tumor mutation burden was linked with improved survival while some alterations were linked with inferior outcomes from treatment with enfortumab vedotin for urothelial carcinoma.

Findings from the second interim analysis of the phase 3 MAGNITUDE study showed the positive benefit of niraparib plus abiraterone and prednisone in metastatic castration-resistant prostate cancer.

Findings from the phase 2 HCRN GU 16-257 trial may help advance a more personalized approach to the management of muscle-invasive bladder cancer.

Guru P. Sonpavde, MD, discusses The Cancer Genome Atlas and key takeaways for community oncologists.

At the final analysis of the ARAMIS study, darolutamide reduced the risk of death by 31% compared with placebo in patients with nonmetastatic castration-resistant prostate cancer.

Though not statistically significant, data from the PROpel study of abiraterone acetate and olaparib were noted to be the longest overall survival results seen in a first-line phase 3 trial in metastatic castration-resistant prostate cancer.